COX-2 Inhibitors Require Three Month Endoscopy Trials For GI Safety
Executive Summary
COX-2 inhibitor agents for arthritis therapy should undergo three-month endoscopy trials to evaluate gastrointestinal safety, FDA's Arthritis Advisory Committee agreed at its March 24 meeting.